KANG Xiao-zheng, YAN Wan-pu, CHEN Ke-neng, TANG Wen-fang. Erlotinib Versus Standard First-Line Chemotherapy as Neoadjuvant Treatment for Stage ⅢA-N2 EGFR-Mutation Positive Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2019, 19(1): 30-33. DOI: 10.12019/j.issn.1671-5144.2019.01.009
|
Citation:
|
KANG Xiao-zheng, YAN Wan-pu, CHEN Ke-neng, TANG Wen-fang. Erlotinib Versus Standard First-Line Chemotherapy as Neoadjuvant Treatment for Stage ⅢA-N2 EGFR-Mutation Positive Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2019, 19(1): 30-33. DOI: 10.12019/j.issn.1671-5144.2019.01.009
|
KANG Xiao-zheng, YAN Wan-pu, CHEN Ke-neng, TANG Wen-fang. Erlotinib Versus Standard First-Line Chemotherapy as Neoadjuvant Treatment for Stage ⅢA-N2 EGFR-Mutation Positive Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2019, 19(1): 30-33. DOI: 10.12019/j.issn.1671-5144.2019.01.009
|
Citation:
|
KANG Xiao-zheng, YAN Wan-pu, CHEN Ke-neng, TANG Wen-fang. Erlotinib Versus Standard First-Line Chemotherapy as Neoadjuvant Treatment for Stage ⅢA-N2 EGFR-Mutation Positive Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2019, 19(1): 30-33. DOI: 10.12019/j.issn.1671-5144.2019.01.009
|
DownLoad: